McKesson reports Q4 adjusted EPS $10.12, consensus $9.83

Reports Q4 revenue $90.82B, consensus $94.2B. “McKesson (MCK) delivered strong fourth quarter performance reporting revenue growth of 19% and Adjusted Earnings per Diluted Share growth of 64%. This marks another year of strong financial results, above our long-term targets, underpinned by operational execution against our strategic priorities, and disciplined and focused capital deployment,” said CEO Brian Tyler. “The strength of our core pharmaceutical distribution business, expansion of our Oncology platform, and continued growth of our differentiated biopharma solutions businesses led to strong results. I want to thank Team McKesson for their hard work and dedication this past quarter and throughout fiscal 2025. As we look ahead to fiscal 2026, we are well positioned to build on our operating momentum, accelerate growth through our strategic priorities, and target investments to accelerate growth and modernize the portfolio.”